A drug-device combination immunotherapy shows promise for patients with metastatic prostate cancer

Results from an early trial by a company with ties to the Lankenau Institute for Medical Research (LIMR), part of Main Line Health, offer hope that a potent form of attack against metastatic castrate-resistant prostate cancer is on the horizon.

Charles J. Link, MD, a LIMR adjunct professor and co-founder and executive chairman of Syncromune, presented phase I trial results on April 7 at the American Association for Cancer Research's annual meeting about a novel combination therapy called SYNC-T that involves freezing part of the tumor and then conducting an infusion of four types of immunotherapy drugs.

Of 13 patients, 11 responded. In five of them, every tumor visible through imaging was gone. The other six had a partial response. The freezing of tumor cells essentially appears to create a personalized cancer vaccine that travels the body.

Read more at: www.aacr.org

About Lankenau Institute for Medical Research

Lankenau Institute for Medical Research (LIMR) is a nonprofit biomedical research institute located on the campus of Lankenau Medical Center and is part of Main Line Health. Founded in 1927, LIMR's mission is to improve human health and well-being. Using its ACAPRENEURIALTM model that integrates academic and entrepreneurial approaches, faculty and staff are devoted to advancing innovative new strategies to address formidable medical challenges including cancer, cardiovascular disease, tissue regeneration, gastrointestinal disorders and autoimmune diseases such as diabetes and arthritis. LIMR's principal investigators conduct basic, preclinical and clinical research, using their findings to explore ways to improve disease detection, diagnosis, treatment and prevention. They are committed to extending the boundaries of human health through technology transfer and training of the next generation of scientists and physicians.